Smith & Nephew plc (SNN) Given Daily Coverage Optimism Rating of 0.21
Media stories about Smith & Nephew plc (NYSE:SNN) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Smith & Nephew plc earned a news impact score of 0.21 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.670966012439 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Smith & Nephew plc (NYSE SNN) traded up 1.31% during midday trading on Thursday, reaching $36.40. 345,967 shares of the company traded hands. The company’s 50-day moving average price is $35.35 and its 200 day moving average price is $33.51. The firm has a market capitalization of $15.94 billion, a PE ratio of 18.53 and a beta of 0.76. Smith & Nephew plc has a 12 month low of $26.97 and a 12 month high of $36.42.
The company also recently announced a semiannual dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th will be issued a $0.246 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a yield of 1.37%.
SNN has been the subject of several recent analyst reports. BidaskClub cut shares of Smith & Nephew plc from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Smith & Nephew plc from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Wednesday, June 7th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $38.00.
ILLEGAL ACTIVITY WARNING: “Smith & Nephew plc (SNN) Given Daily Coverage Optimism Rating of 0.21” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/01/smith-nephew-plc-snn-given-daily-coverage-optimism-rating-of-0-21.html.
Smith & Nephew plc Company Profile
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Stock Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related stocks with our FREE daily email newsletter.